<DOC>
<DOCNO>EP-0632053</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Cyclic adhesion inhibitors
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3812	C07K1475	C07K1478	C07K122	C07K1113	A61P900	C07K700	A61P900	A61P1900	A61P3500	A61K3800	C07K100	A61K3812	C07K764	C07K752	C07K14435	A61P3500	A61K3800	A61P1900	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	C07K	C07K	C07K	C07K	A61P	C07K	A61P	A61P	A61P	A61K	C07K	A61K	C07K	C07K	C07K	A61P	A61K	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K38	C07K14	C07K14	C07K1	C07K1	A61P9	C07K7	A61P9	A61P19	A61P35	A61K38	C07K1	A61K38	C07K7	C07K7	C07K14	A61P35	A61K38	A61P19	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Claimed are cyclopeptides of the formula cyclo-(Arg-B-Asp-D-E) (I) where B = Gly, Ala, -HN-Q-CO- and D and E are independently Gly, -HN-Q-CO-, Ala, Asn, Asp, Asp(OR), Arg, 3-cyclohexyl alanine, Cys, Gln, Glu, His, Ile, Leu, Lys, Lys(Ac), Lys (AcNH2), Lys(AcSH), Met, 3-(2-naphthyl)-alanine, norleucine, ornithine, Phe, 4-halogen-Phe, phenylglycine, proline, 3-(2-pyridyl)-alanine, Ser, Thr, 3-(2-thienyl)-alanine, tetrahydroisoquinoline-3-carbonic acid, Trp, Tyr or Val or their derivs., R = alkyl with 1-6 C-atoms, Hal = F, Cl, Br, I; Q = alkylene with 1-6 C atoms and Ac = alkanoyl with 1-10 C-atoms, where applicable either the D- and L-forms, and the physiological salts thereof. Also claimed is (a) the prodn. of I, (b) a pharmaceutical compsn. including I, and (c) (b's) prodn..
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
MERCK PATENT GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
MERCK PATENT GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DIEFENBACH BEATE
</INVENTOR-NAME>
<INVENTOR-NAME>
FELDING-HABERMANN BRUNHILDE DR
</INVENTOR-NAME>
<INVENTOR-NAME>
HAUBNER ROLAND
</INVENTOR-NAME>
<INVENTOR-NAME>
HOELZEMANN GUENTER DR
</INVENTOR-NAME>
<INVENTOR-NAME>
JONCZYK ALFRED DR
</INVENTOR-NAME>
<INVENTOR-NAME>
KESSLER HORST PROF DR
</INVENTOR-NAME>
<INVENTOR-NAME>
RIPPMANN FRIEDRICH DR
</INVENTOR-NAME>
<INVENTOR-NAME>
WERMUTH JOCHEN
</INVENTOR-NAME>
<INVENTOR-NAME>
DIEFENBACH, BEATE
</INVENTOR-NAME>
<INVENTOR-NAME>
FELDING-HABERMANN, BRUNHILDE, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
HAUBNER, ROLAND
</INVENTOR-NAME>
<INVENTOR-NAME>
HOELZEMANN, GUENTER, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
JONCZYK, ALFRED, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
KESSLER, HORST, PROF. DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
RIPPMANN, FRIEDRICH, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
WERMUTH, JOCHEN
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Cyclopeptides of the formula I

cyclo-(Arg-B-Asp-X-Y)

in which

B
is Gly, Ala, -HN-Q-CO- and
X and Y
in each case independently of one another are
Gly, -HN-Q-CO-, Ala, Asn, Asp, Asp(OR), Arg, Cha,

Cys, Gln, Glu, His, Ile, Leu, Lys, Lys(Ac),
Lys(AcNH
2
), Lys(AcSH), Met, Nal, Nle, Orn, Phe,
4-Hal-Phe, Phg, Pro, Pya, Ser, Thr, Tia, Tic,

Trp, Tyr or Val, where the said amino acid radicals
can also be derivatized,

where, if X is Phe, Y is not Val,
R
is alkyl having 1-6 C atoms,
Hal
is F, Cl, Br or I,
Q
is alkylene having 1-6 C atoms and
Ac
is alkanoyl having 1-10 C atoms,

where, if it is a case of radicals of optically active
amino acids and amino acid derivatives, both the D and

the L forms are included, and also their physiologically
acceptable salts.
An enantiomer or a diastereomer of a compound of
the formula I according to Claim 1.
(a) cyclo-(Arg-Gly-Asp-D-Lys-Val);
(b) cyclo-(Arg-Gly-Asp-D-Phe-Lys);
(c) cyclo-(Arg-Gly-Asp-D-Phe-Gly);
(d) cyclo-(Arg-Gly-Asp-D-Phe-Phe);
(e) cyclo-(Arg-Gly-Asp-D-Phe-Leu);
(f) cyclo-(Arg-Gly-Asp-Phe-D-Leu).
Process for the preparation of a compound of the
formula I according to Claim 1 or one of its salts,

characterized in that it is liberated from one of its
functional derivatives by treating with a solvolysing or

hydrogenolysing agent,

or in that a peptide of the formula II

H-Z-OH

in which

Z
is -Arg-B-Asp-X-Y-

-B-Asp-X-Y-Arg-

-Asp-X-Y-Arg-B-

-X-Y-Arg-B-Asp- or

-Y-Arg-B-Asp-X-,

or a reactive derivative of such a peptide is treated
with a cyclizing agent.
Method for the production of pharmaceutical
preparations, characterized in that a compound of the

formula I according to Claim 1 and/or one of its physiologically
acceptable salts are brought into a suitable

dosage form together with at least one solid, liquid or
semisolid excipient or auxiliary.
Pharmaceutical preparation, characterized in that
it contains at least one compound of the general formula

I according to Claim 1 and/or one of its physiologically
acceptable salts.
Use of compounds of the formula I according to
Claim 1 or their physiologically acceptable salts for the

production of a medicament for the control of diseases.
Compounds of the formula I according to Claim 1
or their physiologically acceptable salts for use in the

control of diseases.
Use of compounds of the formula I according to
Claim 1 for the production of immobilized ligands for

affinity column chromatography.
Use of compounds of the formula I according to
Claim 1 for the purification of integrins by affinity

chromatography.
</CLAIMS>
</TEXT>
</DOC>
